Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

enVVeno Medical (NVNO) Research & Development (2017 - 2020)

enVVeno Medical has reported Research & Development over the past 4 years, most recently at $2.3 million for Q4 2020.

  • Quarterly results put Research & Development at $2.3 million for Q4 2020, up 189.06% from a year ago — trailing twelve months through Dec 2020 was $4.3 million (up 92.75% YoY), and the annual figure for FY2025 was $10.0 million, down 18.52%.
  • Research & Development for Q4 2020 was $2.3 million at enVVeno Medical, up from $758198.0 in the prior quarter.
  • Over the last five years, Research & Development for NVNO hit a ceiling of $2.3 million in Q4 2020 and a floor of $43069.0 in Q3 2017.
  • Median Research & Development over the past 4 years was $424596.0 (2018), compared with a mean of $551612.9.
  • Peak annual rise in Research & Development hit 885.85% in 2018, while the deepest fall reached 16.0% in 2018.
  • enVVeno Medical's Research & Development stood at $349088.0 in 2017, then decreased by 16.0% to $293241.0 in 2018, then surged by 168.66% to $787827.0 in 2019, then surged by 189.06% to $2.3 million in 2020.
  • The last three reported values for Research & Development were $2.3 million (Q4 2020), $758198.0 (Q3 2020), and $706173.0 (Q2 2020) per Business Quant data.